studies

mHCC - 1st line (L1), immune chekpoint inhibitors vs. sorafenib, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsCheckMate 459, 2019 0.85 [0.71; 1.01] IMbrave-150, 2020 0.58 [0.42; 0.80] 0.72[0.50; 1.04]CheckMate 459, 2019, IMbrave-150, 2020277%1,244moderatenot evaluable progression or deaths (PFS)detailed resultsCheckMate 459, 2019 0.93 [0.79; 1.10] IMbrave-150, 2020 0.59 [0.46; 0.75] 0.75[0.48; 1.17]CheckMate 459, 2019, IMbrave-150, 2020289%1,244moderatenot evaluable objective responses (ORR)detailed resultsCheckMate 459, 2019 2.42 [1.48; 3.94] IMbrave-150, 2020 2.77 [1.62; 4.73] 2.57[1.79; 3.69]CheckMate 459, 2019, IMbrave-150, 202020%1,244moderatenot evaluable AE (any grade)detailed resultsIMbrave-150, 2020 0.70 [0.14; 3.50] 0.70[0.14; 3.50]IMbrave-150, 202010%485NAnot evaluable AE (grade 3-4)detailed resultsIMbrave-150, 2020 1.06 [0.72; 1.55] 1.06[0.72; 1.55]IMbrave-150, 202010%485NAnot evaluable AE leading to death (grade 5)detailed resultsIMbrave-150, 2020 0.78 [0.33; 1.82] 0.78[0.33; 1.82]IMbrave-150, 202010%485NAnot evaluable AE leading to treatment discontinuation (any grade)detailed resultsIMbrave-150, 2020 1.61 [0.88; 2.92] 1.61[0.88; 2.92]IMbrave-150, 202010%485NAnot evaluable SAE (any grade)detailed resultsIMbrave-150, 2020 1.38 [0.92; 2.07] 1.38[0.92; 2.07]IMbrave-150, 202010%485NAnot evaluable STRAE (grade 3-4)detailed resultsCheckMate 459, 2019 0.30 [0.22; 0.41] 0.30[0.22; 0.41]CheckMate 459, 201910%743NAnot evaluable TRAE leading to discontinuation (any grade)detailed resultsCheckMate 459, 2019 0.53 [0.28; 1.00] 0.53[0.28; 1.00]CheckMate 459, 201910%743NAnot evaluable Abdominal pain AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.47 [0.12; 1.90] 0.47[0.12; 1.90]IMbrave-150, 202010%485NAnot evaluable Acute kidney injury AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.16 [0.02; 1.51] 0.16[0.02; 1.51]IMbrave-150, 202010%485NAnot evaluable Alopecia AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.47 [0.01; 23.97] 0.47[0.01; 23.97]IMbrave-150, 202010%485NAnot evaluable Anaemia AE (grade 3-4)detailed resultsIMbrave-150, 2020 1.07 [0.32; 3.53] 1.07[0.32; 3.53]IMbrave-150, 202010%485NAnot evaluable Asthenia AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.12 [0.01; 1.05] 0.12[0.01; 1.05]IMbrave-150, 202010%485NAnot evaluable Constipation AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.47 [0.01; 23.97] 0.47[0.01; 23.97]IMbrave-150, 202010%485NAnot evaluable Cough AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.24 [0.01; 7.07] 0.24[0.01; 7.07]IMbrave-150, 202010%485NAnot evaluable Decreased appetite AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.31 [0.09; 1.11] 0.31[0.09; 1.11]IMbrave-150, 202010%485NAnot evaluable Diarrhoea AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.34 [0.12; 1.01] 0.34[0.12; 1.01]IMbrave-150, 202010%485NAnot evaluable Dyspepsia AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.12 [0.01; 2.61] 0.12[0.01; 2.61]IMbrave-150, 202010%485NAnot evaluable Dyspnoea AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.63 [0.14; 2.84] 0.63[0.14; 2.84]IMbrave-150, 202010%485NAnot evaluable Epistaxis AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.24 [0.01; 7.07] 0.24[0.01; 7.07]IMbrave-150, 202010%485NAnot evaluable Fatigue AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.75 [0.24; 2.34] 0.75[0.24; 2.34]IMbrave-150, 202010%485NAnot evaluable Hypertension AE (grade 3-4)detailed resultsIMbrave-150, 2020 1.29 [0.73; 2.28] 1.29[0.73; 2.28]IMbrave-150, 202010%485NAnot evaluable Increase AST AE (grade 3-4)detailed resultsIMbrave-150, 2020 1.39 [0.61; 3.18] 1.39[0.61; 3.18]IMbrave-150, 202010%485NAnot evaluable Increased ALT AE (grade 3-4)detailed resultsIMbrave-150, 2020 2.91 [0.64; 13.19] 2.91[0.64; 13.19]IMbrave-150, 202010%485NAnot evaluable Infusion-related reaction AE (grade 3-4)detailed resultsIMbrave-150, 2020 7.75 [0.44; 135.83] 7.75[0.44; 135.83]IMbrave-150, 202010%485NAnot evaluable Nausea AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.47 [0.03; 7.61] 0.47[0.03; 7.61]IMbrave-150, 202010%485NAnot evaluable Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.02 [0.00; 0.28] 0.02[0.00; 0.28]IMbrave-150, 202010%485NAnot evaluable Proteinuria AE (grade 3-4)detailed resultsIMbrave-150, 2020 4.86 [0.62; 38.30] 4.86[0.62; 38.30]IMbrave-150, 202010%485NAnot evaluable Pruritus AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.47 [0.01; 23.97] 0.47[0.01; 23.97]IMbrave-150, 202010%485NAnot evaluable Pyrexia AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.95 [0.17; 5.23] 0.95[0.17; 5.23]IMbrave-150, 202010%485NAnot evaluable Rash AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.06 [0.00; 1.10] 0.06[0.00; 1.10]IMbrave-150, 202010%485NAnot evaluable Thrombocytopenia AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.95 [0.23; 3.84] 0.95[0.23; 3.84]IMbrave-150, 202010%485NAnot evaluable Vomiting AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.95 [0.09; 10.54] 0.95[0.09; 10.54]IMbrave-150, 202010%485NAnot evaluable Weight decreased AE (grade 3-4)detailed resultsIMbrave-150, 2020 0.24 [0.01; 7.07] 0.24[0.01; 7.07]IMbrave-150, 202010%485NAnot evaluable0.020.01.0relative treatment effectwww.metaEvidence.org2024-07-01 18:51 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 131 - treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,854,374,1073,953,672,1080,862,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,746,745,856,634,861,416,864,769,980,369,743

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons